Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guideline – Venous Thromboembolism in Cancer Patients

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

Ann Oncol. 2023;34(5):452-467.
Falanga A, Ay C, Di Nisio M, et al, on behalf of the ESMO Guidelines Committee

  • Cancer-associated thrombosis is a major health problem that affects morbidity and mortality of people with cancer.
  • Surgical and systemic pharmacological anticancer treatments have a significant impact on the thrombotic risk of patients.
  • Primary thromboprophylaxis may be considered in high-risk ambulatory cancer patients using validated risk models.
  • Anticoagulant treatment of venous thromboembolism in cancer patients is effective but may be associated with increased bleeding.
  • LMWH or DOACs are effective treatments and generally safe options for cancer-associated thrombosis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.